Special Issue

Treatment of Alzheimer Disease

Message from the Guest Editor

Alzheimer's disease (AD) is the most common neurodegenerative disease that represents the principal cause of dementia worldwide. The social and economic burden behind this disease affects families, caregivers and, obviously, patients. Numerous factors are involved in the onset and progression of AD, but the exact mechanisms leading to the accumulation of ⊠-amyloid (AM) protein and the formation of neurofibrillary tangles of tau protein in the brain are still unresolved. In addition to the effort spent searching for new innovative treatments which are able to stop the progression of AD, to date, all treatments available are only applicable to symptomatic patients. Thus, the identification of modifications that accumulate with aging in the AD brain is certainly needed to discover new successful therapeutic approaches. In this Special Issue, "Treatment of Alzheimer Disease", we invite investigators to contribute original research articles and review articles regarding the novel therapeutic approaches to counteract AD progression.

Guest Editor

Dr. Giulia Sita

Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/50611

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

